作者
Raban V Jeger, Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, Gregor Leibundgut, Daniel Weilenmann, Jochen Wöhrle, Stefan Richter, Matthias Schreiber, Felix Mahfoud, Axel Linke, Frank-Peter Stephan, Christian Mueller, Peter Rickenbacher, Michael Coslovsky, Nicole Gilgen, Stefan Osswald, Christoph Kaiser, Bruno Scheller, Peter Buser, Michael Kühne, Michael Zellweger, Christian Sticherling, Bastian Wein, Raphael Twerenbold, Gregor Fahrni, Björn Plicht, Berthold Struck, Ismet Önal, Bodo Cremers, Yvonne Clever, Sebastian Ewen, Stephan Schirmer, Michael Böhm, Andreas Wagner, Bernward Lauer, Georg Stachel, Robert Höllriegel, Ephraim Winzer, Hans Rickli, Peter Ammann, Philipp Haager, Lukas Trachsel, Lucas Joerg, Dominique Nüssli, Hans Roelli, Micha Maeder, Franziska Rohner, Sinisa Markovic, Rima Paliskyte, Dominik Buckert, Belal Awad, Paul Erne, Peiman Jamshidi, Florim Cuculi, Ioannis Kapos, Stefan Toggweiler, Florian Riede, Tudor Pörner, Karsten Lenk, Michel Noutsias, Ralf Surber, Gudrun Dannberg, Markus Franz, Sylvia Otto, Robert Zweiker, Ella NIederl, Sabine Perl, Burkert Pieske, Albrecht Schmidt, Olev Luha, Dirk Von Lewinski, Florian Krackhardt, Behrouz Kherad, Timo Jerichow, Christian Butter, Michael Neuss, Grit Tambor, Frank Hölschermann, Leonhard Bruch, Sebastian Winkler, Corinna Lenz, Mirko Seidel, Boris Keweloh, Alexandra Röttgen, Steffen Bohl, Alexander Wolf, Andreas Hoffmann
发表日期
2018/9/8
期刊
The Lancet
卷号
392
期号
10150
页码范围
849-856
出版商
Elsevier
简介
Background
Drug-coated balloons (DCB) are a novel therapeutic strategy for small native coronary artery disease. However, their safety and efficacy is poorly defined in comparison with drug-eluting stents (DES).
Methods
BASKET-SMALL 2 was a multicentre, open-label, randomised non-inferiority trial. 758 patients with de-novo lesions (<3 mm in diameter) in coronary vessels and an indication for percutaneous coronary intervention were randomly allocated (1:1) to receive angioplasty with DCB versus implantation of a second-generation DES after successful predilatation via an interactive internet-based response system. Dual antiplatelet therapy was given according to current guidelines. The primary objective was to show non-inferiority of DCB versus DES regarding major adverse cardiac events (MACE; ie, cardiac death, non-fatal myocardial infarction, and target-vessel revascularisation) after 12 months. The …
学术搜索中的文章
RV Jeger, A Farah, MA Ohlow, N Mangner… - The Lancet, 2018
